PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 26 of 39 · 913 questions tagged clinical-trials.

913 questions · sorted by votes · page 26 of 39

14 votes1 answer4k views
Is PIONEER-4 a fair comparison of dulaglutide against its comparator arm?

Details up front: PIONEER-4 · dulaglutide. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

14 questions
asked by anja_hellstrom 13k · 6 months ago
14 votes4 answers2.8k views
Does the STEP 2 population resemble anyone asking about semaglutide here?

The specifics, since they change the answer: STEP 2 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them.…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by rae_oyelowo 21k · 2 months ago
14 votes0 answers2.3k views
What did the placebo arm of STEP 2 report for constipation?

The particulars: STEP 2 · constipation. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by gel_pack_warm 13k · 5 months ago
13 votes 5 answers36k views
What does TRIUMPH-3 report at the 4 mg dose level?

Stated plainly: TRIUMPH-3 · 4 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the method…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by hana_petrikova 19k · 2.2 years ago
13 votes3 answers33k views
How do I convert the STEP 8 hazard ratio into an absolute risk reduction?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I have worked this out and I would like someone to find…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
asked by lipid_panel_q 44k · 2.4 years ago
13 votes 5 answers31k views
What does FLOW actually establish about mazdutide?

What I am working with: FLOW · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

14 questions
asked by ayo_fadipe 19k · 22 months ago
13 votes 5 answers31k views
Does the SURMOUNT-OSA population resemble anyone asking about oral semaglutide here?

The case in front of me: SURMOUNT-OSA · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by meniscus_film 34k · 2.3 years ago
13 votes5 answers24k views
What does STEP 5 tell me about vomiting at the 40 mg dose?

Stated plainly: STEP 5 · vomiting · 40 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by plate_count_9k 95k · 2.0 years ago
13 votes 5 answers22k views
What does SELECT actually establish about dulaglutide?

What I have: SELECT · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

14 questions
asked by haze_check 17k · 15 months ago
13 votes3 answers21k views
Does the PIONEER-1 population resemble anyone asking about cagrilintide here?

Stated plainly: PIONEER-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
pcos
pcos

Polycystic ovary syndrome: insulin resistance as the shared mechanism, ovulatory and menstrual outcomes reported on treatment, androgen changes,…

14 questions
asked by void_volume 13k · 23 months ago
13 votes5 answers21k views
Is 10 mg weekly a defensible maintenance dose for oral semaglutide?

Conditions: 10 mg · oral semaglutide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

44 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
asked by rosa_mendieta 13k · 18 months ago
13 votes 5 answers20k views
Does the SURMOUNT-3 population resemble anyone asking about mazdutide here?

Stated plainly: SURMOUNT-3 · mazdutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by tamsin_wray 13k · 23 months ago
13 votes 5 answers16k views
What does SOUL actually establish about a GLP-1 receptor agonist?

What I am working with: SOUL · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by siobhan_deasy 16k · 18 months ago
13 votes5 answers15k views
What is the reported incidence of nausea on a GLP-1 receptor agonist in STEP 8?

Stated plainly: nausea · a GLP-1 receptor agonist · STEP 8. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
pcos
pcos

Polycystic ovary syndrome: insulin resistance as the shared mechanism, ovulatory and menstrual outcomes reported on treatment, androgen changes,…

14 questions
asked by wren_calloway 14k · 19 months ago
13 votes 5 answers13k views
Is ATTAIN-1 a fair comparison of semaglutide against its comparator arm?

The specifics, since they change the answer: ATTAIN-1 · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

14 questions
glucagon-receptor
glucagon-receptor

Glucagon receptor agonism as a deliberate component of dual and tri-agonists: what it adds in energy expenditure and hepatic fat mobilisation, and…

14 questions
asked by valentina_rossi 16k · 15 months ago
13 votes 5 answers12k views
What does TRIUMPH-1 actually establish about cagrilintide?

Setup, so nobody has to ask: TRIUMPH-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by rune_thoresen 14k · 19 months ago
13 votes 4 answers11k views
What is the reported incidence of vomiting on retatrutide in SURMOUNT-4?

Details up front: vomiting · retatrutide · SURMOUNT-4. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by fill_volume 13k · 17 months ago
13 votes 4 answers11k views
What did SURMOUNT-2 do with participants who could not tolerate a step?

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I have read the primary source rather than the summary, which has left me…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
asked by bac_or_bust 37k · 13 months ago
13 votes0 answers11k views
Does the TRIUMPH-3 population resemble anyone asking about ecnoglutide here?

For reference: TRIUMPH-3 · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by g_paskevicius 44k · 11 months ago
13 votes 5 answers9.7k views
Is SURMOUNT-2 a fair comparison of oral semaglutide against its comparator arm?

The case in front of me: SURMOUNT-2 · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by Dr_Ingrid_Baumgartner 39k · 23 months ago
13 votes 5 answers9.3k views
Is STEP 1 a fair comparison of oral semaglutide against its comparator arm?

The case in front of me: STEP 1 · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
cagrisema
cagrisema

A fixed-ratio combination of cagrilintide, a long-acting amylin analogue, with semaglutide, studied in the REDEFINE programme. Questions here…

14 questions
hormones
hormones

Endocrine changes accompanying substantial weight loss: sex hormone binding globulin, testosterone, oestradiol, cortisol and the reproductive…

14 questions
asked by deamidation_watch 43k · 3 months ago
13 votes5 answers8.5k views
What does PIONEER-4 tell me about nausea at the 50 mg dose?

Numbers first: PIONEER-4 · nausea · 50 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by meniscus_film 34k · 15 months ago
13 votes 5 answers8.1k views
Is REDEFINE-1 a fair comparison of mazdutide against its comparator arm?

What I am working with: REDEFINE-1 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by nadia_kowalczyk 14k · 5 months ago
13 votes0 answers8.1k views
What is the reported incidence of nausea on mazdutide in ATTAIN-1?

Setup, so nobody has to ask: nausea · mazdutide · ATTAIN-1. I have read the primary source rather than the summary, which has left me with more questions. I…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by samir_bennani 13k · 22 months ago